By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Warner Chilcott Co. et al. v. Midlothian Laboratories L.L.C.
2:09-cv-02026; filed April 30, 2009 in the District Court of New Jersey
Warner Chilcott Co. et al. v. Mission Pharmacal Co.
2:09-cv-02025; filed April 30, 2009 in the District Court of New Jersey
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 6,521,247 ("Dual Iron Containing Nutritional Supplement," issued February 18, 2003) based on Midlothian's manufacture and sale of its Foltabs and Foltabs DHA prenatal supplements and Misson's manufacture and sale of its CitraNatal DHA, CitraNatal90 DHA, and CitraNatal Rx prenatal supplements. View the Midlothian Laboratories complaint here.
Biogen Idec Ma Inc. v. Doll
1:09-cv-00792; filed April 30, 2009 in the District Court of the District of Columbia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 7,446,173 ("Polymer Conjugates of Interferon Beta-1A and Uses," issued November 4, 2008). View the complaint here.
Pfizer Inc. et al. v. Alphapharm Pty. Ltd. et al.
1:09-cv-00056; filed April 30, 2009 in the Northern District of West Virginia
Pfizer Inc. et al. v. Teva Pharmaceuticals USA Inc. et al.
1:09-cv-00307; filed April 29, 2009 in the District Court of Delaware
The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 6,001,876 ("Isobutylgaba and Its Derivatives for the Treatment of Pain," issued December 14, 1999) and 6,197,819 ("Gamma Amino Butyric Acid Analogs and Optical Isomers," issued March 6, 2001) following a Paragraph IV certification as part of defendant's filing of an ANDA to manufacture a generic version of Pfizer's Lyrica® (pregabalin, used to treat fibromyalgia). View the Teva Pharmaceuticals complaint here.
Pfizer Inc. et al. v. Lupin Ltd. et al.
1:09-cv-00309; filed April 29, 2009 in the District Court of Delaware
Pfizer Inc. et al. v. Actavis Elizabeth LLC et al.
1:09-cv-00311; filed April 29, 2009 in the District Court of Delaware
Pfizer Inc. et al. v. Sandoz Inc.
1:09-cv-00310; filed April 29, 2009 in the District Court of Delaware
The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 6,001,876 ("Isobutylgaba and Its Derivatives for the Treatment of Pain," issued December 14, 1999), 6,197,819 ("Gamma Amino Butyric Acid Analogs and Optical Isomers," issued March 6, 2001), and 5,563,175 ("GABA and L-glutamic Acid Analogs for Antiseizure Treatment," issued October 8, 1996) following a Paragraph IV certification as part of defendant's filing of an ANDA to manufacture a generic version of Pfizer's Lyrica® (pregabalin, used to treat fibromyalgia). View the Lupin complaint here.
Pfizer Inc. et al. v. Cobalt Laboratories Inc. et al.
1:09-cv-00315; filed April 29, 2009 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,563,175 ("GABA and L-glutamic Acid Analogs for Antiseizure Treatment," issued October 8, 1996) and 6,197,819 ("Gamma Amino Butyric Acid Analogs and Optical Isomers," issued March 6, 2001) following a Paragraph IV certification as part of defendant's filing of an ANDA to manufacture a generic version of Pfizer's Lyrica® (pregabalin, used to treat fibromyalgia). View the complaint here.
Pfizer Inc. et al. v. Sun Pharma Global Inc. et al.
1:09-cv-00313; filed April 29, 2009 in the District Court of Delaware
Pfizer Inc. et al. v. Wockhardt Ltd. et al.
1:09-cv-00312; filed April 29, 2009 in the District Court of Delaware
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 6,197,819 ("Gamma Amino Butyric Acid Analogs and Optical Isomers," issued March 6, 2001) following a Paragraph IV certification as part of defendant's filing of an ANDA to manufacture a generic version of Pfizer's Lyrica® (pregabalin, used to treat fibromyalgia). View the Sun Pharma complaint here.
Pfizer Inc. et al. v. Alphapharm Pty Ltd. et al.
1:09-cv-00308; filed April 29, 2009 in the District Court of Delaware
Infringement of U.S. Patent No. 6,001,876 ("Isobutylgaba and Its Derivatives for the Treatment of Pain," issued December 14, 1999) following a Paragraph IV certification as part of defendant's filing of an ANDA to manufacture a generic version of Pfizer's Lyrica® (pregabalin, used to treat fibromyalgia). View the complaint here.
Pronova BioPharma Norge AS v. Par Pharmaceutical Inc. et al.
1:09-cv-00305; filed April 29, 2009 in the District Court of Delaware
Pronova BioPharma Norge AS v. Apotex Corp. et al.
1:09-cv-00304; filed April 29, 2009 in the District Court of Delaware
The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 5,502,077 ("Fatty Acid Composition," issued March 26, 1996) and 5,656,667 (same title, issued August 12, 1997) following a Paragraph IV certification as part of Eagle's filing of an ANDA to manufacture a generic version of Pronova's Lovaza® (omega-3-acid ethyl esters, used to reduce triglyceride levels in adult patients with very high triglyceride levels). View the Par Pharmaceutical complaint here.
Novartis Pharmaceuticals Corp. et al. v. Anchen Pharmaceuticals, Inc.
2:09-cv-02929; filed April 27, 2009 in the Central District of California
Novartis Pharmaceuticals Corp. et al. v. Anchen Pharmaceuticals Inc.
1:09-cv-00294; filed April 24, 2009 in the District Court of New Jersey
Novartis Pharmaceuticals Corp. et al. v. Watson Pharmaceuticals Inc. et al.
0:09-cv-60622; filed April 27, 2009 in the Southern District of Florida
Novartis Pharmaceuticals Corp. et al. v. Watson Pharmaceuticals Inc. et al.
1:09-cv-00292; filed April 24, 2009 in the District Court of New Jersey
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 6,106,864 ("Pharmaceutical Formulations Containing Darifenacin," issued August 22, 2000) following a Paragraph IV certification as part of defendant's filing of an ANDA to manufacture a generic version of Novartis' Enablex® (darifenacin, used to treat symptoms of overactive bladder). View the California Anchen Pharmaceuticals complaint here.
Novartis Pharmaceuticals Corp. et al. v. Teva Pharmaceuticals USA Inc.
1:09-cv-00291; filed April 24, 2009 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,096,890 ("Pyrrolidine Derivatives," issued March 17, 1992) and 6,106,864 ("Pharmaceutical Formulations Containing Darifenacin," issued August 22, 2000) following a Paragraph IV certification as part of defendant's filing of an ANDA to manufacture a generic version of Novartis' Enablex® (darifenacin, used to treat symptoms of overactive bladder). View the complaint here.
Reckitt Benckiser Inc. v. Watson Laboratories, Inc. - Florida et al.
0:09-cv-60609; filed April 24, 2009 in the Southern District of Florida
Infringement of U.S. Patent Nos. 6,372,252 ("Guaifenesin Sustained Release Formulation and Tablets," issued April 16, 2002) and 6,955,821 ("Sustained Release Formulations of Guaifenesin and Additional Drug Ingredients," issued October 18, 2005) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of plaintiff's Mucinex® and Mucinex® DM (guaifenesin, and guaifenesin/dextromethorphan, respectively, used to treat chest congestion). View the complaint here.
Pozen Inc. v. Teva Pharmaceuticals USA Inc.
6:09-cv-00182; filed April 24, 2009 in the Eastern District of Texas
Infringement of U.S. Patent Nos. 6,060,499 ("Anti-migraine Methods and Compositions Using 5-HT Agonists with Long-Acting NSAIDS," issued May 9, 2000) and 6,586,458 ("Methods of Treating Headaches Using 5-HT Agonists in Combination with Long-Acting NSAIDS," issued July 1, 2003), licensed to GlaxoSmithKline, following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of GSK's Treximet® (sumatriptan and naproxen sodium, used to treat migrane attacks). View the complaint here.
Hoffmann-La Roche Inc. v. Doll
1:09-cv-00760; filed April 24, 2009 in the District Court of the District of Columbia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 7,442,776 ("Cancerous Disease Modifying Antibodies," issued October 28, 2008). View the complaint here.
Biogen Idec Ma Inc v. Doll
1:09-cv-00754; filed April 23, 2009 in the District Court of the District of Columbia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 7,442,370 ("Polymer Conjugates of Mutated Neublastin," issued October 28, 2008). View the complaint here.
Comments